On March 8, 2023 ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), reported that Gail Farfel, Ph.D., Chief Executive Officer, will present at the upcoming Oppenheimer 33rd Annual Conference on Monday, March 13, 2023 at 12:30 p.m. ET (Press release, ProMIS Neurosciences, MAR 8, 2023, View Source [SID1234628344]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcasted presentation will be available on ProMIS’ website at www.promisneurosciences.com/news-media/events, and will be available for at least 30 days following the event.